However, due to the substantial mutually exclusive relationship between KRAS and EGFR mutations, the clinical usefulness of KRAS mutation as a selection marker for EGFR-TKIs sensitivity in NSCLC is limited [131]. Here, KRAS is linked to non-small cell lung carcinoma.